Mohseni Saeid, Tavakoli Ali, Ghazipoor Hamid, Pouralimohamadi Neda, Zare Roghayeh, Rampp Thomas, Shayesteh Maryam, Pasalar Mehdi
Department of Persian Medicine, School of Persian Medicine, Babol University of Medical Sciences, Babol, Iran.
Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Front Nutr. 2025 Mar 24;12:1494351. doi: 10.3389/fnut.2025.1494351. eCollection 2025.
Inflammatory Bowel Disease (IBD), encompassing Crohn disease (CD) and ulcerative colitis (UC), presents complex challenges in management due to dysregulated immune responses and genetic predispositions. This study explored the potential of curcumin as an adjunctive therapy in IBD, assessing its efficacy and safety through a systematic review of clinical trials to enhance treatment strategies and outcomes.
To identify placebo-controlled randomized clinical trials on curcumin treatment in IBD, databases such as Medline/PubMed, Scopus, Embase, Web of Knowledge, and Google Scholar were searched till May 2024. Inclusion criteria focused on RCTs comparing curcumin with placebo in IBD patients, with data extraction and analysis conducted using established methodologies and tools for comprehensive synthesis and assessment of study findings.
In this meta-analysis, 13 placebo-controlled RCTs on curcumin treatment in IBD were included after screening 362 records and conducting a full-text review. Most trials focused on UC patients and were published post-2010, utilizing oral curcumin with varying dosages and durations. The analysis showed curcumin's significant efficacy in achieving clinical remission and response in UC patients, with heterogeneity observed. Adverse events and withdrawal rates did not significantly differ between curcumin and placebo groups. In CD patients, curcumin did not show superiority over placebo for clinical and endoscopic remission.
The findings highlight curcumin's potential as a treatment for UC but indicate inconclusive results for CD, emphasizing the need for further research. The multifaceted mechanisms of curcumin's efficacy in IBD involve anti-inflammatory, antioxidant, microbiota modulatory, and immune-regulating properties. Further research is warranted to enhance understanding and treatment efficacy.
炎症性肠病（IBD）包括克罗恩病（CD）和溃疡性结肠炎（UC），由于免疫反应失调和遗传易感性，在管理方面面临复杂挑战。本研究探讨了姜黄素作为IBD辅助治疗的潜力，通过对临床试验的系统评价来评估其疗效和安全性，以改进治疗策略和结果。
为了识别关于姜黄素治疗IBD的安慰剂对照随机临床试验，检索了Medline/PubMed、Scopus、Embase、Web of Knowledge和谷歌学术等数据库，直至2024年5月。纳入标准侧重于在IBD患者中比较姜黄素与安慰剂的随机对照试验，使用既定方法和工具进行数据提取和分析，以全面综合和评估研究结果。
在这项荟萃分析中，在筛选362条记录并进行全文审查后，纳入了13项关于姜黄素治疗IBD的安慰剂对照随机对照试验。大多数试验聚焦于UC患者，且于2010年后发表，使用了不同剂量和疗程的口服姜黄素。分析显示姜黄素在使UC患者实现临床缓解和反应方面具有显著疗效，但存在异质性。姜黄素组和安慰剂组的不良事件和退出率没有显著差异。在CD患者中，姜黄素在临床和内镜缓解方面未显示出优于安慰剂的效果。
研究结果突出了姜黄素作为UC治疗方法的潜力，但表明对CD的结果尚无定论，强调需要进一步研究。姜黄素在IBD中发挥疗效的多方面机制涉及抗炎、抗氧化、微生物群调节和免疫调节特性。有必要进行进一步研究以增进理解并提高治疗效果。
